RHB-104 Shows Promise for Crohn’s Disease Remission in Phase 3 Trial

RHB-104 Shows Promise for Crohn’s Disease Remission in Phase 3 Trial
RedHill Biopharma’s experimental therapy RHB-104 significantly increases the remission and response rates of patients with Crohn’s disease, according to top-line Phase 3 trial results recently announced by the company. The results, showing that the study met all primary and key secondary goals, were discussed in a conference call, which included a slide presentation. RHB-104 is an oral antibiotic combination therapy with potent anti-bacterial and anti-inflammatory properties, targeting
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *